NCT01577745 - A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Solid Tumors

Interventions

BIOLOGICAL

MEDI0639

MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.

Trial Locations (11)

10002

Research Site, New York

44105

Research Site, Cleveland

45201

Research Site, Cincinnati

48103

Research Site, Ann Arbor

77030

Research Site, Houston

90404

Research Site, Los Angeles

98112

Research Site, Seattle

98405

Research Site, Tacoma

06513

Research Site, New Haven

Unknown

Research Site, Boston

Research Site, Minneapolis